Sinovac Receives Nasdaq Delisting Notice Over Late 20-F Filing
Company

Sinovac Receives Nasdaq Delisting Notice Over Late 20-F Filing

Pien Tze Huang's PZH2108 Cancer Pain Drug Enrolls First Phase IIa Patient
CompanyDrug

Pien Tze Huang’s PZH2108 Cancer Pain Drug Enrolls First Phase IIa Patient

Abbott to Acquire Exact Sciences for $21B, Entering Cancer Diagnostics Leadership
CompanyDeals

Abbott to Acquire Exact Sciences for $21B, Entering Cancer Diagnostics Leadership

Henlius Serplulimab Wins BTD for Gastric Cancer Perioperative Treatment, a China First
CompanyDrug

Henlius Serplulimab Wins BTD for Gastric Cancer Perioperative Treatment, a China First

FDA Pilot Program Offers Meeting Minute Clarification to Drug Sponsors
Policy / Regulatory

FDA Pilot Program Offers Meeting Minute Clarification to Drug Sponsors

Reprogenix Closes RMB 500M Series A+ to Advance Diabetes Cell Therapy Pipeline
Others

Reprogenix Closes RMB 500M Series A+ to Advance Diabetes Cell Therapy Pipeline

Pfizer's Hympavzi Wins China Approval as First Weekly Non‑Factor Hemophilia Therapy
CompanyDrug

Pfizer’s Hympavzi Wins China Approval as First Weekly Non‑Factor Hemophilia Therapy

Freenome Roche Cancer Screening Deal Worth Over $200M
CompanyDeals

Freenome Roche Cancer Screening Deal Worth Over $200M

Nona Biosciences Licenses HCAb Platform to Pfizer for Antibody Discovery
CompanyDeals

Nona Biosciences Licenses HCAb Platform to Pfizer for Antibody Discovery

Rock Roc's CAR-M Platform Secures RMB 50M Series A for Macrophage Therapy
CompanyDeals

Rock Roc’s CAR-M Platform Secures RMB 50M Series A for Macrophage Therapy

Kelun-Biotech's Trastuzumab Botidotin HER2 ADC Launches in China After Phase 3 Win vs T-DM1
CompanyDrug

Kelun-Biotech’s Trastuzumab Botidotin HER2 ADC Launches in China After Phase 3 Win vs T-DM1

Regeneron's Libtayo Wins EC Approval for Adjuvant CSCC, 68% Risk Reduction
CompanyDrug

Regeneron’s Libtayo Wins EC Approval for Adjuvant CSCC, 68% Risk Reduction